Date: 2014-11-12
Type of information: Collaboration agreement
Compound: diagnostic platform ‘NEO’
Company: New Oncology (Germany) National Cancer Centre Singapore (NCCS) (Singapore)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: New Oncology’s proprietary diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials.The pan-cancer diagnostic test NEOplus detects actionable genetic alterations with short turn-around times. In contrast to conventional testing, NEOplus identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample. We work with a tumour board comprising renowned cancer experts, facilitating translation of the latest targeted therapy findings into optimized patient care. New Oncology is the molecular diagnostics division of Blackfield AG, a company specialising in cancer genome analysis.
Disease:
Details: * On November 12, 2014, New Oncology announced that it has entered into a collaboration with the National Cancer Centre Singapore (NCCS). Under this agreement, New Oncology will apply its proprietary diagnostic platform ‘NEO’ that enables physicians to select optimal targeted therapies for their patients. NEO provides a fully informative molecular cancer profile from the smallest quantities of patient samples with short turn-around times.
Financial terms: No financial details were disclosed.
Latest news:
